LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 312153

Search options

  1. Article ; Online: Deciphering the molecular mechanism of Bu Yang Huan Wu Decoction in interference with diabetic pulmonary fibrosis via regulating oxidative stress and lipid metabolism disorder.

    Guo, Junfeng / Zhang, Yuwei / Zhou, Rui / Hao, Yanwei / Wu, Xuanyu / Li, Ganggang / Du, Quanyu

    Journal of pharmaceutical and biomedical analysis

    2024  Volume 243, Page(s) 116061

    Abstract: ... but its treatment has yet to be thoroughly investigated. Bu Yang Huan Wu Decoction (BYHWD) is a well-known ...

    Abstract Background: Diabetes mellitus type 2 and pulmonary fibrosis have been found to be closely related in clinical practice. Diabetic pulmonary fibrosis (DPF) is a complication of diabetes mellitus, but its treatment has yet to be thoroughly investigated. Bu Yang Huan Wu Decoction (BYHWD) is a well-known traditional Chinese prescription that has shown great efficacy in treating pulmonary fibrosis with hypoglycemic and hypolipidemic effects.
    Methods: The active ingredients of BYHWD and the corresponding targets were retrieved from the Traditional Chinese Medicine Systematic Pharmacology Database (TCMSP) and SymMap2. Disease-related targets were obtained from the GeneCard, OMIM and CTD databases. GO enrichment and KEGG pathway enrichment were carried out using the DAVID database. AutoDock Vina software was employed to perform molecular docking. Molecular dynamics simulations of proteinligand complexes were conducted by Gromacs. Animal experiments were further performed to validate the effects of BYHWD on the selected core targets, markers of oxidative stress, serum lipids, blood glucose and pulmonary fibrosis.
    Results: A total of 84 active ingredients and 830 target genes were screened in BYHWD, among which 56 target genes intersected with DPF-related targets. Network pharmacological analysis revealed that the active ingredients can regulate target genes such as IL-6, TNF-α, VEGFA and CASP3, mainly through AGE-RAGE signaling pathway, HIF-1 signaling pathway and TNF signaling pathway. Molecular docking and molecular dynamics simulations suggested that IL6-astragaloside IV, IL6-baicalein, TNFα-astragaloside IV, and TNFα-baicalein docking complexes could bind stably. Animal experiments showed that BYHWD could reduce the expression of core targets such as VEGFA, CASP3, IL-6 and TNF-α. In addition, BYHWD could reduce blood glucose, lipid, and MDA levels in DPF while increasing the activities of SOD, CAT and GSH-Px. BYHWD attenuated the expression of HYP and collagen I, mitigating pathological damage and collagen deposition within lung tissue.
    Conclusions: BYHWD modulates lipid metabolism disorders and oxidative stress by targeting the core targets of IL6, TNF-α, VEGFA and CASP3 through the AGE-RAGE signaling pathway, making it a potential therapy for DPF.
    MeSH term(s) Animals ; Tumor Necrosis Factor-alpha ; Pulmonary Fibrosis/drug therapy ; Caspase 3 ; Interleukin-6 ; Blood Glucose ; Lipid Metabolism ; Molecular Docking Simulation ; Diabetes Mellitus, Type 2 ; Oxidative Stress ; Lipid Metabolism Disorders ; Collagen ; Drugs, Chinese Herbal/pharmacology ; Drugs, Chinese Herbal/therapeutic use ; Saponins ; Triterpenes
    Chemical Substances Tumor Necrosis Factor-alpha ; astragaloside A (3A592W8XKE) ; Caspase 3 (EC 3.4.22.-) ; Interleukin-6 ; Blood Glucose ; Collagen (9007-34-5) ; Drugs, Chinese Herbal ; Saponins ; Triterpenes
    Language English
    Publishing date 2024-02-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 604917-5
    ISSN 1873-264X ; 0731-7085
    ISSN (online) 1873-264X
    ISSN 0731-7085
    DOI 10.1016/j.jpba.2024.116061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis: study protocol for a multicenter, randomized, double-blind, placebo-controlled trial.

    Yang, Shu-Guang / Yu, Xue-Qing / Li, Jian-Sheng / Xie, Yang / Zhang, Wei / Ban, Chengjun / Feng, Jihong / Wu, Lei / Lu, Xuechao / Zhao, Limin / Meng, Yong / Zhou, Miao / He, Yong / Luo, Weixian

    Trials

    2022  Volume 23, Issue 1, Page(s) 725

    Abstract: ... limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal ...

    Abstract Background and rationale: Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal compound, has shown promising efficacy in reducing frequencies of acute exacerbations, improving exercise capacity the quality of life of patients with idiopathic pulmonary fibrosis. This study is to evaluate the efficacy and safety of JHG for IPF.
    Subjects and methods: This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 312 idiopathic pulmonary fibrosis patients will be enrolled and randomly allocated to one of the two groups with 1:1. After a 2-week washout period, 52-week treatment will also be performed for all the patients. Patients in the experimental group and the control group will be given JHG and JHG placebo, respectively. Outcome measures including acute exacerbations, pulmonary function, dyspnea, exercise capacity, and quality of life will be evaluated in this study.
    Discussion: Based on our previous study, it is hypothesized that JHG will reduce acute exacerbations; improve exercise capacity, pulmonary function, and quality of life; and delay the disease progression-free. High-level evidence-based support for TCM in IPF will also be obtained in this study.
    Trial registration: ClinicalTrials.gov NCT04187690. Register on December 11, 2019.
    MeSH term(s) Double-Blind Method ; Humans ; Idiopathic Pulmonary Fibrosis/diagnosis ; Idiopathic Pulmonary Fibrosis/drug therapy ; Lung ; Multicenter Studies as Topic ; Quality of Life ; Randomized Controlled Trials as Topic ; Treatment Outcome
    Language English
    Publishing date 2022-09-02
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-022-06684-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis

    Shu-guang Yang / Xue-qing Yu / Jian-sheng Li / Yang Xie / Wei Zhang / Chengjun Ban / Jihong Feng / Lei Wu / Xuechao Lu / Limin Zhao / Yong Meng / Miao Zhou / Yong He / Weixian Luo

    Trials, Vol 23, Iss 1, Pp 1-

    study protocol for a multicenter, randomized, double-blind, placebo-controlled trial

    2022  Volume 10

    Abstract: ... limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal ...

    Abstract Abstract Background and rationale Idiopathic pulmonary fibrosis is a critical disease with a poor prognosis. Although different studies have been conducted for the treatment of idiopathic pulmonary fibrosis, limited treatments are available. Jin-shui Huan-xian granule (JHG), which is a Chinese medicine herbal compound, has shown promising efficacy in reducing frequencies of acute exacerbations, improving exercise capacity the quality of life of patients with idiopathic pulmonary fibrosis. This study is to evaluate the efficacy and safety of JHG for IPF. Subjects and methods This is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 312 idiopathic pulmonary fibrosis patients will be enrolled and randomly allocated to one of the two groups with 1:1. After a 2-week washout period, 52-week treatment will also be performed for all the patients. Patients in the experimental group and the control group will be given JHG and JHG placebo, respectively. Outcome measures including acute exacerbations, pulmonary function, dyspnea, exercise capacity, and quality of life will be evaluated in this study. Discussion Based on our previous study, it is hypothesized that JHG will reduce acute exacerbations; improve exercise capacity, pulmonary function, and quality of life; and delay the disease progression-free. High-level evidence-based support for TCM in IPF will also be obtained in this study. Trial registration ClinicalTrials.gov NCT04187690. Register on December 11, 2019
    Keywords Idiopathic pulmonary fibrosis ; Traditional Chinese medicine ; Jin-shui Huan-xian granule ; Randomized controlled trial ; Study protocol ; Medicine (General) ; R5-920
    Subject code 610
    Language English
    Publishing date 2022-09-01T00:00:00Z
    Publisher BMC
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Jie-Yu-He-Huan Capsule Ameliorates Anxiety-Like Behaviours in Rats Exposed to Chronic Restraint Stress via the cAMP/PKA/CREB/BDNF Signalling Pathway.

    Geng, Xiwen / Wu, Hongyun / Li, Zifa / Li, Chuanfen / Chen, Dan / Zong, Jiancheng / Liu, Zimin / Wei, Sheng / Peng, Wei

    Oxidative medicine and cellular longevity

    2021  Volume 2021, Page(s) 1703981

    Abstract: ... these animals using the open-field test, elevated plus-maze test, and light-dark box test. Jie-Yu-He-Huan ...

    Abstract Chronic stress is a critical factor in the aetiology of anxiety disorders; however, in the clinic, enduring and preventive measures are not available, and therapeutic drugs are associated with inevitable side effects. Our study established an anxiety rat model using chronic restraint stress (CRS) and assessed these animals using the open-field test, elevated plus-maze test, and light-dark box test. Jie-Yu-He-Huan capsule (JYHH), a Chinese medicine formula, was used as a preventative drug. The HPA axis-mediated release of corticotropin-releasing hormone, adrenocorticotropic hormone, and corticosterone from the hypothalamus was tested. In the hippocampus and prefrontal cortex, concentrations of 5-HT and its metabolite 5-hydroxyindoleacetic acid, as well as monoamine oxidase A, glucocorticoid receptor, and 5-HT1A receptor expression levels, were measured. Furthermore, we examined protein and mRNA expression of cAMP-PKA-CREB-BDNF pathway components. The results showed that JYHH had a significant preventative effect on the anxiety-like behaviour induced by CRS and prevented abnormal changes in the HPA axis and 5-HT system. Furthermore, CRS inhibited the cAMP-PKA-CREB-BDNF pathway, which returned to normal levels following JYHH treatment. This might be the underlying molecular mechanism of the antianxiety effect of JYHH, which could provide a new clinical target for preventative anxiolytic drugs for chronic stress.
    MeSH term(s) Animals ; Anti-Anxiety Agents/pharmacology ; Anxiety/drug therapy ; Brain-Derived Neurotrophic Factor/metabolism ; Corticosterone/pharmacology ; Disease Models, Animal ; Hypothalamo-Hypophyseal System/metabolism ; Hypothalamo-Hypophyseal System/physiopathology ; Male ; Pituitary-Adrenal System/metabolism ; Pituitary-Adrenal System/physiopathology ; Rats, Wistar ; Restraint, Physical ; Stress, Psychological/complications ; Rats
    Chemical Substances Anti-Anxiety Agents ; Brain-Derived Neurotrophic Factor ; Corticosterone (W980KJ009P)
    Language English
    Publishing date 2021-10-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2455981-7
    ISSN 1942-0994 ; 1942-0994
    ISSN (online) 1942-0994
    ISSN 1942-0994
    DOI 10.1155/2021/1703981
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Book: Shun pao huan kai che

    Liu, Jinqi / Li, Zhigang

    2011  

    Title variant Shun pao huan kaiche ; Shun-p'ao-huan-k'ai-ch'e / Liu Chin-ch'i, Li Chih-kang p'ien
    Author's details Liu Jinqi, Li Zhigang bian
    Keywords Chinesisches Schach
    Language Chinese
    Size 362 S
    Publisher Jing ji guan li chu ban she
    Publishing place Beijing
    Document type Book
    Note In chines. Schr.
    ISBN 9787509614129 ; 7509614120
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  6. Book ; Audio / Video: Huan zhu ge ge

    Li, Ping

    : di yi bu = Princess Huan Zhu

    2005  

    Author's details [Regie: Li Ping]
    Language Chinese
    Size 4 DVDs (Region 1-6,8), 500 Min
    Publishing place China
    Document type Book ; Audio / Video
    Note Audiosprache: Chinesisch ; Untertitel: Chinesisch (Kurzzeichen)
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  7. Book ; Audio / Video: Huan zhu ge ge

    Li, Ping

    : di yi bu = Princess Huan Zhu

    2005  

    Author's details [Regie: Li Ping]
    Language Chinese
    Size 4 DVDs (Region 1-6,8), 540 Min
    Publishing place China
    Document type Book ; Audio / Video
    Note Audiosprache: Chinesisch ; Untertitel: Chinesisch (Kurzzeichen)
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  8. Book: Mo huan chufang

    Li, Zhiyi

    Magic kitchen

    2003  

    Author's details [Regie: Li Zhiyi]
    Language Chinese
    Size 2 VCDs, 105 Min
    Publishing place Hongkong
    Document type Book
    Note Audiosprachen: Chinesisch, Kantonesisch
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  9. Book: Huan qiu zhong guo xue sheng bao

    Chen, Zhanqi / Jiang, Yasha / Jing, Li

    (Wan qing zhen xi qi kan hui bian : 晚清珍稀期刊汇编 ; / Jiang ya sha, jing li, chen zhan qi zhu bian ; 6)

    2009  

    Institution Quan guo tu shu guan wen xian suo wei fu zhi zhong xin (China)
    全国图书馆文献缩微复制中心 (China)
    Series title Wan qing zhen xi qi kan hui bian : 晚清珍稀期刊汇编
    / Jiang ya sha, jing li, chen zhan qi zhu bian ; 6
    Language Chinese ; English
    Size 661 p
    Publisher Quan guo tu shu guan wen xian suo wei fu zhi zhong xin
    Publishing place Bei jing
    Document type Book
    Database Former special subject collection: coastal and deep sea fishing

    More links

    Kategorien

  10. Article ; Online: Metabolite identification of seven active components of Huan-Nao-Yi-Cong-Fang in rat plasma using high-performance liquid chromatography combined with hybrid ion trap/time-of-flight mass spectrometry.

    Wang, Minchao / Lu, Yanzhen / Liu, Jiangang / Li, Hao / Wei, Yun

    Biomedical chromatography : BMC

    2016  Volume 30, Issue 2, Page(s) 269–279

    Abstract: Huan-Nao-Yi-Cong-Fang (HNYCF) is a potential prescription in treating Alzheimer's disease. Seven ...

    Abstract Huan-Nao-Yi-Cong-Fang (HNYCF) is a potential prescription in treating Alzheimer's disease. Seven constituents [ferulic acid (FA), 2,3,5,4'-tetrahydroxystilbene-2-O-β-d-glucoside (THSG), berberine hydrochloride (BHCl), emodin, ginsenoside Rg1 (Rg1), ginsenoside Re (Re) and ginsenoside Rb1 (Rb1)] have been used as quality chemical markers of HNYCF owing to their biological significance and high contents in crude plant materials. This study explored the metabolites of the seven bioactive components in rat plasma to give useful data for further study of the action mechanism of HNYCF. LC/MS-IT-TOF was used to simultaneously characterize the metabolites of the seven components. Using the combination of MetID Solution 1.0 software and accurate mass measurements, the metabolites of HNYCF were reliably characterized. Their structures were elucidated based on the accurate MS(2) spectra and comparisons of their changes in accurate molecular masses and fragment ions with those of parent compounds. A total of five parent active compounds (BHCl, emodin, Rg1, Rb1 and Re) and 10 metabolites were found from the rat plasma 2 h after oral administration of HNYCF dosage, of which two metabolites of emodin were observed for the first time. The proposed metabolic pathways of the bioactive components in the rat plasma are helpful for further studies on the pharmacokinetics and real active compound forms of this drug.
    MeSH term(s) Administration, Oral ; Animals ; Berberine/blood ; Berberine/chemistry ; Berberine/pharmacokinetics ; Chromatography, High Pressure Liquid/methods ; Drugs, Chinese Herbal/administration & dosage ; Drugs, Chinese Herbal/chemistry ; Drugs, Chinese Herbal/pharmacokinetics ; Emodin/blood ; Emodin/chemistry ; Emodin/pharmacokinetics ; Ginsenosides/blood ; Ginsenosides/chemistry ; Ginsenosides/pharmacokinetics ; Male ; Mass Spectrometry/methods ; Rats ; Rats, Wistar
    Chemical Substances Drugs, Chinese Herbal ; Ginsenosides ; Berberine (0I8Y3P32UF) ; Emodin (KA46RNI6HN)
    Language English
    Publishing date 2016-02
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632848-9
    ISSN 1099-0801 ; 0269-3879
    ISSN (online) 1099-0801
    ISSN 0269-3879
    DOI 10.1002/bmc.3546
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top